B-cell Epitope Peptide Based Cancer Vaccine
Creative Biolabs has the world's leading vaccine development team, especially in the field of cancer vaccines, bringing together experts who are proficient in various types of cancer vaccines, and has developed a number of effective cancer vaccine platforms.
B-cell Epitope Peptide Based Cancer Vaccine
As one of the diseases with high mortality rates, cancer has been a heavy burden for patients, their families, and society for a long time. Although some progress has been made in the treatment of solid tumors, most of the patients still die of cancer. Therefore, research on cancer and its treatment still has a long way to go. Using B-cell or T-cell epitope peptides as vaccines to participate in the body's immune system and stimulate it to produce antibodies with immune memory, this strategy has been proven to have significant advantages in aspects of treating cancers compared to infusion of humanized monoclonal antibodies. Because the latter tend to have additional toxicity.
The strategy for treating cancer using the B cell epitope peptide vaccine is to link the identified B cell epitope peptide to an immunogenic protein (because the immunogenicity of the epitope peptide is weak) and finally add an adjuvant. A highly immunogenic vaccine containing a target epitope is thus prepared. These target epitopes are usually some normal self-proteins, such as HER2 or PD1. After the B cell epitope peptide vaccines containing these epitopes enter the body, they can induce the body's immune system to produce antibodies or peptide mimics against these self-antigens. Resulting antibodies or peptide mimics can play a role in interfering with cellular signals. In addition, antibodies produced after immunization are often a mixture of a variety of antibodies that bind to different parts of the vaccine antigen. This is one of the advantages of B cell epitope peptide vaccines over monoclonal antibodies that can only bind to one target in vivo.
Strengths of B-cell Epitope Peptide Based Cancer Vaccine
- Relatively simple production and low cost
- Can produce polyclonal antibodies, thus reducing tumor resistance to the vaccine
- Higher safety than synthetic monoclonal antibodies
- Sustainable production of antibodies in vivo to inhibit tumor recurrence
- Can be administered by simple routes such as subcutaneous or intramuscular injection
Creative Biolabs is committed to providing the highest quality technical support to vaccine researchers worldwide. In more than a decade of development, we have been persevering in this philosophy in a practical and devout manner. The launch of a series of high-quality research and development platforms and countless experimental results praised by customers commend our efforts. If you have any need for vaccine development, we will be your most reliable partner!
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
